University of Texas MD Anderson Cancer Center

📅 Upcoming

🕒 Recent(90d)

News

• Psilocybin proves promising in neuropathic pain mouse study
  Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
  fiercebiotech · 1mo ago
• FDA panel endorses broader use of certain peptides
  In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supportin…
  biopharma_dive · 2mo ago
• Trump administration warns more than 500 hospitals to provide more price information or face fines
  The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.
  stat · 3mo ago
• Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
  Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.
  onclive · 4mo ago
• FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
  The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
  onclive · 4mo ago
• Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
  Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.
  onclive · 4mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 4mo ago
• UT MD Anderson Shares Latest Research Breakthroughs
  The University of Texas MD Anderson Cancer Center released recent oncology research highlights.
  onclive · 4mo ago
• Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
  Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
  onclive · 5mo ago
• Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
  Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.
  onclive · 5mo ago